VivoSeq
Neurology

Childhood Absence Epilepsy

7

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Childhood Absence Epilepsy is an early-stage landscape with 7 programs across 6 companies. The most active players are Glaxo Dba Glaxosmithkline, Parkedale, AbbVie. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 3P

Parkedale

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3UCB logo

UCB

3 programs

Phase 3Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

ApprovedJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Active, not recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Active, not recruiting·UCB logoUCB·Phase 3·NCT04666610·153 enrolled
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY
Active, not recruiting·UCB logoUCB·Phase 3·NCT06315322·70 enrolled
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
Completed·—·Phase 3·NCT00088452·453 enrolled
A Pilot Study of Topiramate in Childhood Absence Epilepsy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210574·12 enrolled
A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
Completed·TThe Cleveland Clinic·N/A·NCT00361010·20 enrolled
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Completed·UCB logoUCB·Phase 3·NCT05109234·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)